The Finance Behind the Science
The history of biotech is littered with promising therapies that never reached patients.
Some fail because the science was wrong. Others fail because funding ran out before the science had a chance to prove itself.
The history of biotech is littered with promising therapies that never reached patients.
Some fail because the science was wrong. Others fail because funding ran out before the science had a chance to prove itself.
For Australian biotech company Actinogen Medical, the coming months represent a defining period as it advances Xanamem, its novel cortisol-targeting treatment for Alzheimer's disease, through the pivotal XanaMIA Phase 2b/3 clinical trial program. Alongside the main study, the company is also progressing its Open Label Extension program, designed to provide additional long-term safety and efficacy data.
CFO Mag
Elit facilisis maecenas euismod vulputate. Dignissim natoque nascetur donec urna in vel vitae.
We have the capacity and broad expertise to develop one-off projects or complex on-going multi-layered campaigns. We provide the strategies and create the resource material to get the job done!
